LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 658

Suchoptionen

  1. Buch ; Überordnung: Cutaneous melanoma

    Balch, Charles M. / Atkins, Michael B. / Garbe, Claus / Gershenwald, Jeffrey E. / Halpern, Allan C. / Kirkwood, John M.

    (Springer reference)

    2020  

    Verfasserangabe Charles M. Balch, Michael B. Atkins, Claus Garbe, Jeffrey E. Gershenwald, Allan C. Halpern, John M. Kirkwood [und 3 weitere] editors
    Serientitel Springer reference
    Sprache Englisch
    Erscheinungsverlauf 2020-9999
    Ausgabenhinweis Sixth edition
    Verlag Springer
    Erscheinungsort Cham
    Erscheinungsland Schweiz
    Dokumenttyp Buch ; Überordnung (Einzelbände anzeigen)
    HBZ-ID HT020364139
    ISBN 978-3-030-05068-9 ; 9783030050702 ; 3-030-05068-8 ; 303005070X
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

  2. Buch: Cutaneous melanoma / Volume 1

    Balch, Charles M. / Atkins, Michael B. / Garbe, Claus / Gershenwald, Jeffrey E. / Halpern, Allan C. / Kirkwood, John M.

    2020  

    Verfasserangabe Charles M. Balch, Michael B. Atkins, Claus Garbe, Jeffrey E. Gershenwald, Allan C. Halpern, John M. Kirkwood [und 3 weitere] editors
    Überordnung Cutaneous melanoma
    Sprache Englisch
    Umfang xxix, 894 Seiten, Illustrationen, Diagramme
    Erscheinungsland Schweiz
    Dokumenttyp Buch
    HBZ-ID HT020400491
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  3. Buch: Cutaneous melanoma / Volume 2

    Balch, Charles M. / Atkins, Michael B. / Garbe, Claus / Gershenwald, Jeffrey E. / Halpern, Allan C. / Kirkwood, John M.

    2020  

    Verfasserangabe Charles M. Balch, Michael B. Atkins, Claus Garbe, Jeffrey E. Gershenwald, Allan C. Halpern, John M. Kirkwood [und 3 weitere] editors
    Überordnung Cutaneous melanoma
    Sprache Englisch
    Umfang xxix Seiten, Seite 897 - 1510, Illustrationen
    Erscheinungsland Schweiz
    Dokumenttyp Buch
    HBZ-ID HT020400498
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  4. Buch ; Konferenzbeitrag: Integrins in cancer: novel therapeutic approaches

    Kirkwood, John M.

    [... based on the symposium presented to the 31st congress of the European Society of Medical Oncology on September 29, 2006, in Istanbul]

    (Oncology ; 21,9, Suppl. 3)

    2007  

    Verfasserangabe guest ed. John M. Kirkwood
    Serientitel Oncology ; 21,9, Suppl. 3
    Überordnung
    Sprache Englisch
    Umfang 24 S. : Ill.
    Verlag PRR
    Erscheinungsort Melville, NY
    Erscheinungsland Vereinigte Staaten
    Dokumenttyp Buch ; Konferenzbeitrag
    HBZ-ID HT015292944
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  5. Buch: Strategies in adjuvant therapy

    Kirkwood, John M.

    2000  

    Verfasserangabe ed. by John M. Kirkwood
    Sprache Englisch
    Umfang XI, 255 S. : graph. Darst.
    Verlag Dunitz
    Erscheinungsort London
    Erscheinungsland Vereinigtes Königreich
    Dokumenttyp Buch
    HBZ-ID HT012743663
    ISBN 1-85317-317-7 ; 978-1-85317-317-2
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  6. Artikel: Immunotherapy in Melanoma: Recent Advances and Future Directions.

    Knight, Andrew / Karapetyan, Lilit / Kirkwood, John M

    Cancers

    2023  Band 15, Heft 4

    Abstract: The use of immunotherapy in the treatment of advanced and high-risk melanoma has led to a striking improvement in outcomes. Although the incidence of melanoma has continued to rise, median survival has improved from approximately 6 months to nearly 6 ... ...

    Abstract The use of immunotherapy in the treatment of advanced and high-risk melanoma has led to a striking improvement in outcomes. Although the incidence of melanoma has continued to rise, median survival has improved from approximately 6 months to nearly 6 years for patients with advanced inoperable stage IV disease. Recent understanding of the tumor microenvironment and its interplay with the immune system has led to the explosive development of novel immunotherapy treatments. Since the approval of the therapeutic cytokines interleukin-2 and interferon alfa-2 in the 1990s, the development of novel immune checkpoint inhibitors (ICIs), oncolytic virus therapy, and modulators of the tumor microenvironment have given way to a new era in melanoma treatment. Monoclonal antibodies directed at programmed cell death protein 1 receptor (PD-1) and its ligand (PDL-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) have provided robust activation of the adaptive immune system, restoring immune surveillance leading to host tumor recognition and destruction. Multiple other immunomodulatory therapeutics are under investigation to overcome resistance to ICI therapy, including the toll-like receptor-9 (TLR-9) and 7/8 (TLR-7/8) agonists, stimulator of interferon genes (STING) agonists, and fecal microbiota transplantation. In this review, we focus on the recent advances in immunotherapy for the treatment of melanoma and provide an update on novel therapies currently under investigation.
    Sprache Englisch
    Erscheinungsdatum 2023-02-09
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15041106
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel: Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma.

    Rohatgi, Anjali / Kirkwood, John M

    Frontiers in oncology

    2021  Band 11, Seite(n) 640314

    Abstract: The advent of first and second-generation immune checkpoint blockade (ICI) has resulted in improved survival of patients with metastatic melanoma over the past decade. However, the majority of patients ultimately progress despite these treatments, which ... ...

    Abstract The advent of first and second-generation immune checkpoint blockade (ICI) has resulted in improved survival of patients with metastatic melanoma over the past decade. However, the majority of patients ultimately progress despite these treatments, which has served as an impetus to consider a range of subsequent therapies. Many of the next generation of immunotherapeutic agents focus on modifying the immune system to overcome resistance to checkpoint blockade. ICI resistance can be understood as primary, or acquired-where the latter is the most common scenario. While there are several postulated mechanisms by which resistance, particularly acquired resistance, occurs, the predominant escape mechanisms include T cell exhaustion, upregulation of alternative inhibitory checkpoint receptors, and alteration of the tumor microenvironment (TME) into a more suppressive, anti-inflammatory state. Therapeutic agents in development are designed to work by combating one or more of these resistance mechanisms. These strategies face the added challenge of minimizing immune-related toxicities, while improving antitumor efficacy. This review focuses upon the following categories of novel therapeutics: 1) alternative inhibitory receptor pathways; 2) damage- or pathogen-associated molecular patterns (DAMPs/PAMPs); and 3) immune cell signaling mediators. We present the current state of these therapies, including preclinical and clinical data available for these targets under development.
    Sprache Englisch
    Erscheinungsdatum 2021-03-01
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2021.640314
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Buch: Molecular diagnosis and treatment of melanoma

    Kirkwood, John M.

    1998  

    Verfasserangabe ed. by John M. Kirkwood
    Schlagwörter Melanoma / therapy ; Melanoma / diagnosis ; Molecular Biology ; Melanom ; Molekularpathologie ; Therapie
    Schlagwörter Malignes Melanom ; Melanocytoblastom ; Melanozytoblastom ; Melanosarkom ; Melanoma maligna ; Medizinische Behandlung ; Behandlung ; Krankenbehandlung
    Sprache Englisch
    Umfang XIII, 314 S. : Ill., graph. Darst.
    Verlag Dekker
    Erscheinungsort New York u.a.
    Erscheinungsland Vereinigte Staaten
    Dokumenttyp Buch
    HBZ-ID HT008877481
    ISBN 0-8247-0102-X ; 978-0-8247-0102-4
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Cancer vaccine induces potent T cell responses - but is it enough?

    Rohatgi, Anjali / Kirkwood, John M

    Nature reviews. Clinical oncology

    2020  Band 17, Heft 12, Seite(n) 721–722

    Mesh-Begriff(e) CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; Cancer Vaccines/therapeutic use ; Humans ; Melanoma ; RNA
    Chemische Substanzen Cancer Vaccines ; RNA (63231-63-0)
    Sprache Englisch
    Erscheinungsdatum 2020-09-25
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-020-00437-1
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Developing agents for the therapeutic prevention of melanoma: can the assessment of cutaneous precursor lesions help?

    Maguire, William F / Kirkwood, John M

    Future oncology (London, England)

    2020  Band 16, Heft 9, Seite(n) 413–415

    Mesh-Begriff(e) Anticarcinogenic Agents/therapeutic use ; Biomarkers, Tumor ; Chemoprevention ; Clinical Trials as Topic ; Drug Development ; Humans ; Melanoma/pathology ; Melanoma/prevention & control ; Nevus/pathology ; Patient Selection ; Skin Neoplasms/pathology ; Skin Neoplasms/prevention & control
    Chemische Substanzen Anticarcinogenic Agents ; Biomarkers, Tumor
    Sprache Englisch
    Erscheinungsdatum 2020-02-26
    Erscheinungsland England
    Dokumenttyp Editorial
    ZDB-ID 2274956-1
    ISSN 1744-8301 ; 1479-6694
    ISSN (online) 1744-8301
    ISSN 1479-6694
    DOI 10.2217/fon-2020-0012
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang